Jason Zemansky
Stock Analyst at B of A Securities
(4.71)
# 119
Out of 4,784 analysts
33
Total ratings
69.57%
Success rate
32.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $92 → $96 | $77.99 | +23.09% | 9 | Mar 20, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $22 → $17 | $8.17 | +108.08% | 5 | Feb 19, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $7.05 | +311.35% | 2 | Nov 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $13.18 | +135.20% | 3 | Aug 15, 2024 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $1.50 | +66.67% | 5 | Jun 20, 2024 | |
| CYTK Cytokinetics | Maintains: Neutral | $70 → $60 | $43.19 | +38.92% | 3 | May 23, 2024 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $9 → $10 | $1.03 | +870.87% | 4 | May 12, 2023 | |
| ALLK Allakos | Maintains: Buy | $145 → $155 | $0.23 | +67,262.02% | 2 | Dec 13, 2021 |
Insmed
Mar 20, 2025
Maintains: Buy
Price Target: $92 → $96
Current: $77.99
Upside: +23.09%
Arcus Biosciences
Feb 19, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $8.17
Upside: +108.08%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $7.05
Upside: +311.35%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $13.18
Upside: +135.20%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $1.50
Upside: +66.67%
Cytokinetics
May 23, 2024
Maintains: Neutral
Price Target: $70 → $60
Current: $43.19
Upside: +38.92%
Werewolf Therapeutics
May 12, 2023
Maintains: Buy
Price Target: $9 → $10
Current: $1.03
Upside: +870.87%
Allakos
Dec 13, 2021
Maintains: Buy
Price Target: $145 → $155
Current: $0.23
Upside: +67,262.02%